Skip to main content
Premium Trial:

Request an Annual Quote

FDA Questions Whether Genomic Health s Oncotype Dx Should Have Obtained Pre-Market Approval

NEW YORK, Jan. 30 (GenomeWeb News) - The US Food and Drug Administration has asked to meet with Genomic Health CEO Randy Scott to discuss the company's Oncotype diagnostic for breast cancer, according to an FDA letter.

In the letter, dated Jan. 23, the agency's Office of In Vitro Diagnostic Device Evaluation and Safety stated that the FDA has no record of a pre-market review of the test. It asked that Genomic Health set up a meeting with OIVD at its "earliest convenience to discuss the nature and appropriate regulatory status of your technology, and the least burdensome ways that Genomic Health may fulfill any premarket review requirements that may apply."

Genomic Health said on Friday it intended to comply with the letters request for a meeting "in the near future."

 

OIVD "has reviewed reports indicating that Genomic Health is marketing the Oncotype DX ... [as one that predicts] distant disease recurrence ... [and asseses] ... a patient's benefit from certain types of chemotherapy. Under section 201(h) the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. § 321(h)), any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part or accessory, which is intended for use in the diagnosis of disease or other conditions is a device.

 

"We have no record that such a test has been the subject of premarket review by FDA," according to the letter. "We invite you to meet with us at your earliest convenience to discuss the nature and appropriate regulatory status of your technology, and the least burdensome ways that Genomic Health may fulfill any premarket review requirements that may apply."

Letter can be found 

here.
The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.